Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder
← Find more feeds

news.bms.com

Bristol Myers Squibb Press Releases

Get the latest updates from Bristol Myers Squibb Press Releases directly as they happen.

Follow now 288 followers

Latest posts

Last updated 4 days ago

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

4 days ago

Bristol Myers Squibb Announces Dividend

14 days ago

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

15 days ago

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

19 days ago

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

19 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

20 days ago

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

29 days ago

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

about 1 month ago

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

about 1 month ago

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

about 1 month ago

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

about 1 month ago

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

about 2 months ago

Sign up to continue

Try Feeder for free

Everything you care about in one place

Try Feeder now